Renovaro Inc. (2Q5.SG)

1.3600 -0.0060 (-0.44%) As of 08:07AM CEST. Market open.

Renovaro Inc.

2080 Century Park East
Suite 906
Los Angeles, CA 90067
United States
305 918 1980
https://renovarobio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12

Key executives

Name	Title	Pay	Exercised	Year born
Hon. Mark R. Dybul M.D.	CEO, Director & Member of HBV Scientific Advisory Board	709.85k	N/A	1964
Dr. Francois Binette M.Sc., Ph.D.	COO and Executive VP for Research & Development	468.27k	N/A	1964
Dr. Serhat Gümrükcü	Co-Founder & Inventor	N/A	N/A	N/A
Mr. Simon Tarsh	Interim Chief Financial Officer	N/A	N/A	1962
Mr. Greg Duczynski Ph.D.	Senior Vice President for Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Corporate governance

Renovaro Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.